The Methodist Hospital Research Institute

The Methodist Hospital Research Institute, a nonprofit biomedical research organization and division of The Methodist Hospital in Houston, Texas, acts as a federal grant recipient and research prime across a broad portfolio of NIH-funded basic, translational, and clinical research in cancer, infectious diseases, immunology, and neuroscience, with no federal contract prime awards or SBA set-aside designations.

The institute's federal grant work spans discovery research, clinical trials, and workforce development across a dense portfolio of NIH institutes and centers. Recent representative grants include a $2.71 million NIAID award (August 2025) developing self-adjuvanted mRNA vaccines against Mycobacterium tuberculosis; a $1.4 million Defense Health Agency grant (September 2024) on biomarker discovery in amyotrophic lateral sclerosis; a $1.029 million National Eye Institute award (May 2026) on mitochondrial-based cell therapy for age-related macular degeneration; a $846 thousand NIAID grant (August 2025) establishing a nanofluidic drug-delivery resource program for antiretroviral research in nonhuman primates; and smaller awards from the National Cancer Institute, National Heart Lung and Blood Institute, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and National Institute of Diabetes and Digestive and Kidney Diseases. Grant work spans both investigator-initiated research (R01, R21, K-mechanism career development awards) and center or program grants (cooperative agreements including a multi-project bladder cancer center and phase II breast cancer treatment trials). The institute also holds one Other Transaction IDV awarded October 2023 by Joint PEO Chemical and Biological Defense with a $10.5 million ceiling for monoclonal antibody discovery and engineering platform development.

Customer concentration among NIH institutes is pronounced. The National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Heart Lung and Blood Institute collectively account for the majority of recent grant volume and funding. The Defense Health Agency represents the second-largest customer, funding military-relevant translational research in oncology, neurodegenerative disease, and burn injury. Award activity has grown consistently: 36 awards in 2022, 46 in 2023, 63 in 2024, and 61 in 2025, with 15 awards logged through November 2026. Fifty-eight awards face completion within the next twenty-four months, creating recompete exposure across cancer biology, vaccine development, and organ-regeneration research areas.

The institute operates as a prime recipient on 345 of 469 total awards (74% split), with the remainder as a subcontractor to universities and research centers. Named sub-award relationships show The Methodist Hospital Research Institute delivering specialized services to prime recipients including Baylor College of Medicine, MD Anderson Cancer Center, Mayo Clinic, University of Pennsylvania, Yale University, Stanford University, and NIH-funded consortia (ARTFL LEFFTDS on frontotemporal dementia, ALLFTD, ADNI, and PROVIDENT vaccine-development alliances). The institute also subcontracts to smaller teams from University of Texas Health Science Center at Houston, University of Pittsburgh, Northwestern University, and international partners. Across SCI-reported service contracts, the institute documented 66.3 FTEs in FY2024 as a named subcontractor under federal service contracts, though SCI captures only a narrow slice of research delivery (contracts above $150,000) and excludes grant-funded work, which represents the bulk of the institute's federal research portfolio.

The institute's research capability portfolio emphasizes mechanism-driven translational science bridging basic immunology, molecular oncology, regenerative medicine, and infectious disease. Core research themes include T-cell engineering and CAR-T cell optimization, mRNA vaccine platform development, microbiota-immune interactions, metabolic programming in cancer and inflammation, organoid and tissue-engineering platforms, and neuroplasticity. The institute conducts clinical trials, directs animal models (nonhuman primates, transgenic mice, surgical models), maintains biorepository infrastructure (tissue bank, plasma samples, imaging archives), and operates specialized cores for RNA chemistry, mass cytometry, flow cytometry, transcriptomics, and proteomics. Workforce development is represented through training program grants (NEURALCODR for neural control of organ systems, AMR-TPT for antimicrobial resistance training, and NSF-funded robotics and engineering education partnerships).

Administrative oversight is centralized at 6565 Fannin Street in Houston, part of the Texas Medical Center. Work is performed at that Houston location and at affiliated Methodist hospitals in the greater Houston area (Willowbrook, Sugarland, San Jacinto, West Houston). Teaming extends to University of Colorado-Denver on a DART resource program and to other consortium partners contributing to multi-site NIH cohort studies (MESA, ADNI, ARTFL LEFFTDS, REACT-AF, LUCID, HEMO).